PURPOSE: To compare the long-term outcomes of peripheral retinal cryoablation to conventional treatment for active @entity2038 . DESIGN: Retrospective, interventional, comparative case series. METHODS: Review at a single institution was conducted to compare the effect of cryotherapy to eyes with @entity2038 to those receiving conventional therapy (topical, regionally injected, or oral @entity228 therapy). Best-corrected visual acuity (VA), complications, resolution of @entity1103 ( @entity1103 ), and anterior chamber and vitreous @entity32 were assessed. RESULTS: One hundred thirty-six eyes were treated conventionally, 50 eyes were treated with cryotherapy. Median follow-up was 60.8  months (range 8.1-223.1  months) in the cryotherapy group and 45.0  months (range 3.1-339.0  months) in the controls. There were no significant differences in baseline VA, anterior chamber and vitreous @entity32 , presence of @entity1103 , and prior use of regional @entity228 injections. VA improved over time in the cryotherapy group (slope of  -0.0018 logMAR units per month; P  = .023) but declined in the controls (slope of  +0.0011 logMAR units per month; P  = .023). Kaplan-Meier survival estimates demonstrated faster times to resolution of anterior chamber cell, vitreous cell, and @entity1103 in the cryotherapy-treated eyes. Hazard ratios of remission (adjusted for confounding factors) for vitreous cell and @entity1103 for those treated with cryotherapy compared to controls were 4.73 (95% confidence interval 1.63, 13.63; P  = .004) and 6.85 (95% confidence interval 1.06, 44.78; P  = .044), respectively. No ocular complications were identified in the cryotherapy group. CONCLUSIONS: These data suggest that peripheral retinal cryoablation therapy is an effective treatment for active @entity2038 and may be better than conventional regional @entity228 injections and oral @entity228 therapy for induction of remission.

Peripheral Cryoablation for Treatment of Active XXXX : Long-Term Outcomes of a Retrospective Study.

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity2038 :: ('MESH:D015868', 'Disease') :: ['pars planitis'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['CME', 'cystoid macular edema']
@entity2038 :: (MESH:D015868,Disease) :: ['Pars Planitis']
